ES2119735T3 - Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones. - Google Patents

Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones.

Info

Publication number
ES2119735T3
ES2119735T3 ES89101295T ES89101295T ES2119735T3 ES 2119735 T3 ES2119735 T3 ES 2119735T3 ES 89101295 T ES89101295 T ES 89101295T ES 89101295 T ES89101295 T ES 89101295T ES 2119735 T3 ES2119735 T3 ES 2119735T3
Authority
ES
Spain
Prior art keywords
ifn
purification
beta2
human
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101295T
Other languages
English (en)
Inventor
Michel Revel
Menachem Rubinstein
Yves Mory
Louise Chen
Daniela Novick
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL85204A external-priority patent/IL85204A0/xx
Priority claimed from IL8837588A external-priority patent/IL88375A/en
Priority claimed from IL88376A external-priority patent/IL88376A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2119735T3 publication Critical patent/ES2119735T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS MONOCLONALES DE IFN - BETA 2/IL - 6 Y A LAS HIBRIDONAS QUE LOS PRODUCEN, ASI COMO A LA PRODUCCION Y PURIFICACION DE IFN - BETA 2/IL - 6 GLUCOSILADO Y NO GLUCOSILADO. LA PROTEINA ES UTIL PARA EL TRATAMIENTO DEL CANCER DE MAMA, LEUCEMIA, ENFERMEDADES INFECCIOSAS Y ALTERACIONES DE CELULAS DE LA MEDULA.
ES89101295T 1988-01-26 1989-01-25 Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones. Expired - Lifetime ES2119735T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL85204A IL85204A0 (en) 1988-01-26 1988-01-26 Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
US19358088A 1988-05-13 1988-05-13
IL8837588A IL88375A (en) 1988-11-14 1988-11-14 Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
IL88376A IL88376A0 (en) 1988-11-14 1988-11-14 Pharmaceutical compositions containing interferon-beta 2

Publications (1)

Publication Number Publication Date
ES2119735T3 true ES2119735T3 (es) 1998-10-16

Family

ID=27452320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101295T Expired - Lifetime ES2119735T3 (es) 1988-01-26 1989-01-25 Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones.

Country Status (7)

Country Link
EP (1) EP0326120B1 (es)
JP (1) JP2725818B2 (es)
AT (1) ATE165010T1 (es)
AU (1) AU621852B2 (es)
CA (1) CA1341588C (es)
DE (1) DE68928641T2 (es)
ES (1) ES2119735T3 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006370A1 (en) * 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Synthetic interleukin-6
JPH0331215A (ja) * 1989-06-27 1991-02-12 Ajinomoto Co Inc 制癌療法支持剤
DE3939706C1 (es) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
WO1991007986A1 (en) * 1989-12-04 1991-06-13 Schering Corporation Method of treating septic shock
IT1247484B (it) * 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
WO1996025433A1 (en) * 1995-02-15 1996-08-22 Mount Sinai School Of Medicine Of The City University Of New York B cell differentiation and proliferation factors and methods for obtaining and using the same
EP0871472A4 (en) * 1995-10-27 2001-05-30 Amrad Operations Pty Ltd CYTOKINES AND THEIR USE IN THE TREATMENT AND / OR PROPHYLAXIS OF BREAST CANCER
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (ja) 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
JP4987484B2 (ja) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体結合が低下した抗癌抗体
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2336181A1 (en) * 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6
DK1966245T3 (da) 2005-12-30 2011-07-18 Merck Patent Gmbh Anti-CD19-Antistoffer med reduceret immunogenicitet
CN101351475B (zh) 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172496A (ja) * 1983-03-18 1984-09-29 Kyowa Hakko Kogyo Co Ltd モノクロ−ナル抗体
JPH0657157B2 (ja) * 1984-11-09 1994-08-03 忠三 岸本 Ｂ細胞分化因子の製造法
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
CA2011450C (en) * 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor

Also Published As

Publication number Publication date
AU621852B2 (en) 1992-03-26
DE68928641T2 (de) 1998-08-13
CA1341588C (en) 2009-01-06
EP0326120B1 (en) 1998-04-15
EP0326120A3 (en) 1990-05-02
JPH029394A (ja) 1990-01-12
DE68928641D1 (de) 1998-05-20
JP2725818B2 (ja) 1998-03-11
AU2881389A (en) 1989-07-27
EP0326120A2 (en) 1989-08-02
ATE165010T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
ES2119735T3 (es) Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones.
PH25120A (en) Replicable expression vehicle and process of preparation thereof
NO176665C (no) Fremgangsmåte for fremstilling av ikke-glykosylert IL-6 og vektor for utskillelse derav
BG44877A3 (bg) Метод за експресия на ген,кодиращ човешки имунен интерферон
DE69131699D1 (de) Verändertes menschliches iL-6
MC1553A1 (fr) Proteine d'interferon immunitaire humain et son procede de production
DE69129421D1 (de) Interleukin 2 enthaltende rekombinante Immunkonjugate für die Therapie
MC1623A1 (fr) Procede de production d'un polypeptide
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
DE68928710D1 (de) T-Zellen-Wachstumsfaktor
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
ATE140979T1 (de) Reinigung von rekombinantem, menschlichem interleukin-3
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
FI922770A (fi) Bcrf1-proteinerna som inhibitorer av y-interferon.
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
EP0516845A4 (en) NEW MEGAKARYOCYTIC COLONY-STIMULATING FACTOR AND METHOD FOR THE PRODUCTION THEREOF.
EP0672684A4 (en) NOVEL STIMULATION FACTOR OF MEGACARYOCYTATIC COLONIES AND PRODUCTION THEREOF.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 326120

Country of ref document: ES